Skip to content
Tecentriq(atezolizumab)
Tecentriq (atezolizumab) is an antibody pharmaceutical. Atezolizumab was first approved as Tecentriq on 2016-05-18. It is used to treat non-small-cell lung carcinoma and urinary bladder neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, non-small-cell lung carcinoma, small cell lung carcinoma, transitional cell carcinoma, and urologic neoplasms. The pharmaceutical is active against programmed cell death 1 ligand 1.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Tecentriq
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Atezolizumab
Tradename
Proper name
Company
Number
Date
Products
TecentriqatezolizumabGenentechN-761034 RX2016-05-18
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
tecentriqBiologic Licensing Application2021-02-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
non-small-cell lung carcinoma—D002289—
urinary bladder neoplasms—D001749C67
Agency Specific
FDA
EMA
Expiration
Code
atezolizumab, Tecentriq, Genentech, Inc.
2029-12-09Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FF: Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors
— L01FF05: Atezolizumab
HCPCS
Code
Description
J9022
Injection, atezolizumab, 10 mg
Clinical
Clinical Trials
659 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD00228934762315123
NeoplasmsD009369C80504342483
Liver neoplasmsD008113EFO_1001513C22.0142182645
Lung neoplasmsD008175C34.9071221119
Hepatocellular carcinomaD006528C22.04921217
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5019346—253
Triple negative breast neoplasmsD06472614208—137
Urologic neoplasmsD014571C64-C6813193—635
Small cell lung carcinomaD0557528186—331
MelanomaD00854515171—129
Urinary bladder neoplasmsD001749C679223——29
Colorectal neoplasmsD01517913154——28
Renal cell carcinomaD00229212135——26
Ovarian neoplasmsD010051EFO_0003893C569105——19
Uterine cervical neoplasmsD0025835101——15
Show 27 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C16710———13
Head and neck neoplasmsD00625877———13
Non-hodgkin lymphomaD008228C85.995———10
SarcomaD01250938———8
GlioblastomaD005909EFO_000051565———7
Kidney neoplasmsD007680EFO_0003865C6434——17
CholangiocarcinomaD018281C22.135———7
Squamous cell neoplasmsD01830715———6
Biliary tract neoplasmsD001661C24.925———5
LymphomaD008223C85.942———5
Show 63 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Kidney diseasesD007674EFO_0003086N081————1
Urologic diseasesD014570N39.91————1
Neoplasms by histologic typeD0093701————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Adenocarcinoma of lungD0000771921————1
Abdominal neoplasmsD0000081————1
Idiopathic pulmonary fibrosisD054990J84.1121————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Budd-chiari syndromeD006502EFO_1000966I82.0————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameATEZOLIZUMAB
INNatezolizumab
Description
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), hepatocellular carcinoma, and alveolar soft part sarcoma. It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)ATEZOLIZUMAB
Structure (InChI/SMILES or Protein Sequence)
>5XXY:H|heavy chain of atezolizumab fab EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAY LQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTMDPGGSHHHHHHHH >5XXY:L|light chain of atezolizumab fab DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Identifiers
PDB5X8L, 5XXY
CAS-ID1380723-44-3
RxCUI1792776
ChEMBL IDCHEMBL3707227
ChEBI ID—
PubChem CID—
DrugBankDB11595
UNII ID52CMI0WC3Y (ChemIDplus, GSRS)
Target
Agency Approved
CD274
CD274
Organism
Homo sapiens
Gene name
CD274
Gene synonyms
B7H1, PDCD1L1, PDCD1LG1, PDL1
NCBI Gene ID
29126
Protein name
programmed cell death 1 ligand 1
Protein synonyms
B7 homolog 1, B7-H1, CD274, CD274 antigen, PDCD1 ligand 1
Uniprot ID
Q9NZQ7
Mouse ortholog
Cd274 (60533)
programmed cell death 1 ligand 1 (Q9EP73)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Tecentriq - Roche
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 22,063 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9,767 adverse events reported
View more details